Uses of Blaztere

Blaztere drug has the main active ingredient alendronic acid in the form of alendronic monohydrate and other excipients. This is a non-steroidal anti-inflammatory drug that is used in the treatment and prevention of osteoporosis.

Blaztere drug has the main active ingredient alendronic acid in the form of alendronic monohydrate and other excipients in a sufficient amount. This is a non-steroidal anti-inflammatory drug, which is used in the treatment and prevention of osteoporosis.
Blaztere is prepared in the form of lyophilized powder for injection. Packing is a large pill box and includes 3 small boxes.
1.1. Pharmacodynamics of active ingredient alendronic acid: Active ingredient Alendronate sodium is an inhibitor of bone resorption.
1.2. Pharmacokinetics of active ingredient alendronic acid: Absorption: According to preclinical studies, when administered intravenously at a dose of 1 mg/kg, active ingredient alendronate is transiently distributed in soft tissues but then redistributed. bone or excreted in the urine. The binding of alendronic acid to proteins in human plasma is approximately 78%. Metabolism: There is no evidence that alendronate is metabolised in humans. Elimination: Following a single intravenous dose of 10 mg, the renal clearance of alendronate is 71 ml/min. Plasma drug concentrations decreased by more than 95% within 6 hours after intravenous administration. 1.3. Effects of active ingredients alendronic acid: Alendronic acid is an aminobisphosphonate that inhibits specific bone resorption. Preclinical studies have shown that alendronic acid accumulates selectively at sites of active bone resorption, where alendronate inhibits the activity of osteoclasts. Clinical studies have shown that preclinical treatment with drugs containing the active ingredient alendronic acid can significantly increase bone mass in the spine, femoral neck, and trochanter. However, after 1 to 2 years of treatment, if this therapy is stopped, the increase in bone mass cannot be maintained. That proves that daily treatment must be continued to maintain the effectiveness of the treatment.

Blaztere is indicated for the treatment of the following conditions:
Treatment of osteoporosis, Blaztere increases bone mass and prevents fractures, including hip, wrist and vertebrae (vertebral compression fractures). . For the prevention of osteoporosis, alendronate may be used for women at risk for osteoporosis or for those wishing to maintain bone mass and reduce the risk of future fractures. Prevention and treatment of osteoporosis caused by the use of corticosteroid drugs. Treating people with Paget's disease (a condition in which bones become weak and brittle) or who are at risk for complications later in the disease.

How to use and dose of Blaztere drug should be prescribed by the doctor treating the disease.
Do not arbitrarily use or adjust the dose prescribed by the doctor.

In clinical studies, adverse reactions to Blaztere were generally mild and generally did not require discontinuation of the drug. The rate of undesirable effects increased significantly in the treatment of Paget's bone disease with the treatment dose of 40mg/day, mainly adverse effects in the gastrointestinal tract.
Other undesirable effects when using Blaztere, including:
For the central nervous system: headache, dizziness accompanied by dizziness. For the digestive system: Flatulence, acid reflux, esophageal ulcers, difficulty swallowing, abdominal distension. For the skin: Appearance of rash, erythema (rare) For the effect: Gastritis. You need to proactively inform your treating doctor or medical professional if you experience other serious side effects while using Blaztere.

In order to minimize the adverse interactions of Blaztere, the patient should inform the doctor about the drugs, herbs, and health care products being used for the doctor to consider and prescribe. prescription appropriately.

Blaztere is contraindicated in the following cases:
People with esophageal malformations that delay esophageal emptying, for example, stricture or no dilation of the esophageal cardia. Person unable to stand or sit upright for at least 30 minutes. People with hypersensitivity to the main ingredient alendronic acid or to any ingredient in the preparation. People with low calcium in the blood. Above is all information about Blaztere drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Blaztere to treat the disease at home, because there may be unwanted side effects to health.